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Abstract
Background: Breast and cancer screening uptake has been found to be lower among women with serious mental
illness (SMI). This study aims to corroborate these findings in the UK and to identify variation in screening uptake by
illness/treatment factors, and primary care consultation frequency.
Methods: Linked population-based primary and secondary care data from the London borough of Lambeth (UK)
were used to compare breast and cervical screening receipt among linked eligible SMI patients (n = 625 and n = 1393),
to those without SMI known only to primary care (n = 106,554 and n = 25,385) using logistic regression models
adjusted first for socio-demographic factors and second, additionally for primary care consultation frequency.
Results: Eligible SMI patients were less likely to have received breast (adjusted odds ratio (OR) 0.69, 95 %
confidence interval (CI), 0.57 - 0.84, p < 0.001) or cervical screening (adjusted OR 0.72, CI: 0.60 - 0.85, p < 0.001).
Schizophrenia diagnosis, depot injectable antipsychotic prescription, and illness severity and risk were associated
with the lowest odds of uptake of breast (adjusted ORs 0.46 to 0.59, all p < 0.001) and cervical screening (adjusted
ORs 0.48 - 0.65, all p < 0.001). Adjustments for consultation frequency further reduced effect sizes for all subgroups
of SMI patient, in particular for cervical screening.
Conclusions: Women with SMI are less likely to receive breast and cervical cancer screening than comparable
women without SMI. Higher primary care consultation rates among SMI patients is likely a mediating factor
between SMI status and uptake, particularly for cervical screening - a service organised in primary care. To tackle
health disparities linked to SMI, efforts at increasing screening uptake are key and should be targeted at women
with other markers of illness severity or risk, beyond SMI status alone.
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Background
People with serious mental illness (SMI), including
schizophrenia and bipolar disorder, have higher cancer
mortality than others of the same age in the same
population without SMI, and there is some evidence
that this excess disproportionately affects women [1–3].
Cancer screening reduces cancer mortality; reducing
cancer incidence and improving survival [4]. Three
recent systematic reviews have found suboptimal cancer
screening rates in people with mental disorders. These
reviews have included a range of diagnoses, ranging
from emotional distress to diagnosed SMI. Where evi-
dence has been disaggregated by type of mental disorder,
those with SMI are found to have the lowest odds of
screening compared to those without mental ill health
[5–7]. Further, the majority of studies reviewed originate
from the United States so it is not clear how these re-
sults translate into the United Kingdom (UK) context
with universal free access to healthcare and organised
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population-based screening programmes. Absence of
cost barriers, and organised screening, have been shown
to reduce inequalities in screening coverage, [8, 9] hence
more equitable coverage for people with SMI might be
expected in the UK.
The Quality and Outcomes Framework (QOF) is a
primary care reward and incentive programme which
annually records general practice (GP) achievement
against clinical and organisational targets and was in-
troduced in 2004 [10]. Targets include measures aimed
at improving the physical health care of people with
SMI, such as blood pressure monitoring and cervical
cancer screening. It is unclear whether such incentivisa-
tion results in more widespread uptake of screening.
Barriers to participation in screening programmes
among people with experience of mental illness include
factors at the service, practitioner, and service user level
[11]. Routinely available clinical data sources can be
used on a larger scale to investigate specific barriers to
screening such as lack of contact with a primary care
provider, social deprivation, and factors related to the
type and severity of mental illness. The ability to inves-
tigate these processes has previously been restricted as
data on physical health diagnoses, monitoring and
management are mainly recorded in primary care, while
detailed classification of SMI diagnosis and mental state
is mainly recorded in secondary mental health care
records.
This study uses data from a population-based linkage
between primary and secondary care records in the
London borough of Lambeth (UK) to extend previous
knowledge about the uptake of breast and cancer
screening in the SMI population; addressing the follow-
ing questions:
1. Is breast and cervical cancer screening uptake lower
for people registered in primary care with SMI
compared to those without SMI?
2. Does frequency of contact with primary care
explain differences in screening rates between
those with and without SMI?
3. Are there psychological factors that predict lower
screening uptake within the SMI group?
Methods
Setting & data sources
Lambeth is an ethnically diverse borough, with a greater
number of Black Caribbean and Black African residents,
although fewer South Asian residents than most other
areas of London [12] and has high levels of deprivation
overall [13]. Pseudonymised primary care data were
extracted on 31st October 2013 from the computerised
medical records of all except one GP practice (n = 48;
the missing GP practice had an incompatible IT system)
within Lambeth, as part of Lambeth DataNet (LDN).
LDN collects demographic data and data on GP con-
sultations, prescriptions, and (QOF) clinical target
achievement, as well as clinical information about non-
QOF conditions. LDN thus contributed a population of
366,317 registered patients. Secondary care data came
from the Clinical Record Interactive Search (CRIS), [14]
an application allowing research access to pseudony-
mised electronic health record data from the South
London and the Maudsley NHS Foundation Trust
(SLaM). CRIS additionally provides searchable access to
de-identified text (unstructured data) from the clinical
record, and a range of natural language programming
(NLP) applications have been developed to auto-extract
structured data from text fields [15].
Data linkage
CRIS and LDN data were linked and stored by the
SLaM Clinical Data Linkage Service (CDLS), which
provides a safe haven environment with strict govern-
ance arrangements. Data were linked using encrypted
NHS numbers, which were subsequently removed and
destroyed such that the linked dataset became fully
anonymised.
Measures
Primary care data from Lambeth DataNet (LDN)
Data extracted from LDN included 2012/13 QOF-
defined SMI status (recorded on the QOF Mental
Health register with a diagnosis of schizophrenia, bipo-
lar affective disorder and other psychoses), [10] gender,
year of birth, ethnicity, and 2011 defined lower super
output area (LSOA). These are geographic areas de-
signed to improve the reporting of small area statistics
in England and Wales, and include a mean population
of 1500 [16]. Approximate age was calculated by sub-
tracting year of birth from the year of data extraction;
information on the LSOA of each patient was used to
determine the level of social deprivation in their area
using the Index of Multiple Deprivation (IMD-2010)
and a conversion from 2001 LSOA to 2011 LSOA
values [17]. Frequency of primary care consultation
was calculated as the mean number of primary care
consultations (including GP, nurse, face-to-face, and
telephone) over the three years between October 2010
and 31 October 2013. A binary variable was created to
distinguish low (median or below) and high (above me-
dian) mean annual number of consultations. Consult-
ation data were coded as missing for two practices
which had incorrectly entered data for 2013 GP face-
to-face appointments and for numbers entered as nega-
tive values. Lastly, data were extracted to identify those
who had ever been recorded as having received breast
cancer screening (mammography) and cervical cancer
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screening. The population eligible for mammography
was defined as females aged 50 to 70 years inclusive,
while that eligible for cervical cancer screening was de-
fined as females aged 25 to 64 years inclusive. To as-
sess adherence to QOF guidelines, those who had
received a mammography screen any time in the last
three years were identified as recently screened and
distinguished from those who had been recorded as be-
ing screened outside of the guideline period. Similarly,
those who had received a cervical cancer screen any
time in the last three years for those aged up to
49 years, or any time in the last five years for those
aged 50-64 were identified as recently screened as per
recommended guidelines. For both cervical and breast
screening, those with a recent screen were coded as 1,
while those never screened were coded as 0.
Secondary mental health care measures from CRIS
ICD-10 diagnostic codes [18] for any primary or second-
ary diagnosis of schizophrenia, bipolar affective disorder,
and schizoaffective disorder or other non-organic psych-
oses were extracted (ICD-10 codes F20-29, F25, F31). A
binary indicator of higher SMI severity was created
which ascertained and coded as 1, any patients with a
recorded mental health inpatient stay, treatment under
the Mental Health Act, difficulty managing their physical
health as recorded in a clinical risk assessment; or con-
tact with Assertive Outreach, Crisis team or A&E liaison
team. A separate SMI indicator of ‘risk’ was developed,
identifying patients with a history of violent or offending
behavior using data from a risk assessment violence and
aggression subscale. This coded SMI patients as one if had
ever had a recorded history of violence, non-compliance,
or a forensic history – and as 0 if none of these issues
were recorded. In addition, data were extracted on
whether or not the patient had ever been recorded with
a prescription of antipsychotics - including a marker of
depot injectable medication. Table 1 illustrates a sum-
mary of variables, variable descriptions and data
sources.
Statistical analyses
Primary care records were used to define SMI status.
Those identified in primary care with QOF-defined SMI
were compared to those without QOF-defined SMI, who
were not linked to secondary care records. Those identi-
fied in primary care with SMI but who were not linked,
and those who were linked but not recorded in primary
care with SMI, were not included in these analyses, as
the study aimed to extend prior research by examining
SMI characteristics recorded in secondary care associ-
ated with screening uptake (see Fig. 1). Descriptive
analyses including Pearson’s chi squared tests were
used to compare socio-demographic characteristics and
consultation frequency between patients with and without
SMI patients who were eligible for mammography and/or
cervical cancer screening. Separate logistic regression
models were run to compare the likelihood of being re-
corded with a recent breast or cervical screen (versus
those never screened) among patients with SMI overall,
among patients recorded with specific SMI characteristics
and among non-SMI patients. Including non-SMI patients
as the comparator in analyses was designed to ease
interpretation across analyses. Unadjusted models and
models adjusting for socio-demographic characteristics
and additionally for primary care consultation fre-
quency were run. Separate analyses were run, but are
not presented, to include those who had ever been
screened in the numerator (not necessarily within the
guideline period) to examine any differences in patterns
of association. P-values, unadjusted and adjusted odds
ratios (OR) and 95 % confidence intervals (CI) are
shown. All analyses were conducted using STATA v12
[19].
Results
Linkage sample
Overall, data were obtained for LDN patients aged 16
years or over on 31st October 2013 (N = 295,301); of
these, 8.1 % (n = 23,919) were known to secondary men-
tal health care. Among those patients with linked pri-
mary and secondary care records, n = 4056 (16.9 % of
linked sample, 1.37 % of LDN population aged 16+ years
overall) were recorded as having SMI by their GP in
LDN and were denoted as the SMI group. Overall,
270,669 patients (91.7 % of LDN population) were not
recorded with SMI in primary care or linked to second-
ary care, comprising the group identified without
SMI (Fig. 1).
Study sample
Patients eligible for cancer screening
Study sample derivation is illustrated in Fig. 1. We identi-
fied 26,010 women in LDN eligible for mammographic
screening and 107,947 women eligible for cervical screen-
ing, of whom 625 (2.4 %) and 1393 (1.3 %) respectively
were recorded in primary care records as having SMI and
were also known to secondary mental health services
(Fig. 1). Among the eligible populations for breast and
cervical cancer screening, SMI status was associated
with belonging to an ethnic minority group, greater
deprivation, and more frequent primary care consulta-
tions. Among those eligible for cervical cancer screening,
SMI status was also associated with older age, although
this association was not observed for patient eligible for
breast screening (Table 2).
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Cancer screening uptake by SMI status
As illustrated in Fig. 1 of the eligible population for can-
cer screening, n = 17,981 (70.8 %) and n = 405 (64.8 %) of
non-SMI and SMI patients respectively had ever been
screened for breast cancer while n = 87,196 (65.7 %) and
n = 1184 (85.0 %) of non-SMI and SMI patients respect-
ively had ever been screened for cervical cancer. The
proportion of eligible patients who had received a re-
cent screen was lower among both SMI and non-SMI
patients (Fig. 1).
Comparison of screening according to QOF guidelines
indicated that SMI patients were less likely to have a
record of recent mammography screening compared to
those without SMI (Table 3). Adjustments for socio-
demographic characteristics, and additionally, for
primary care consultation frequency increased the
strength of the negative association such that the odds
of recent screening were almost 40 % lower among
those identified with SMI.
In unadjusted models SMI status was positively asso-
ciated with recent cervical screening according to
guidelines (Table 3). Adjustment for socio-demographic
differences between the groups reversed this association -
such that being recorded with SMI was associated with
reduced odds of recent cervical cancer screening, and
adjustment for primary care consultation rate further
increased the negative effect size such that the odds of
cervical screening were almost 60 % lower among SMI
patients.
Variation in screening receipt by mental illness
characteristics
The odds of screening receipt varied across different sub-
groups of women with SMI in adjusted models (Table 3).
Those with schizophrenia, those ever prescribed depot in-
jectable medication and those ever identified with any in-
dicator of risk or severity, were the least likely to have
been screened for breast cancer. Similarly, a diagnosis of
schizophrenia and receipt of depot injectable antipsychotic
medication were associated with the lowest odds of cer-
vical cancer screening in adjusted models.
Discussion
After accounting for sociodemographic differences (par-
ticularly differences in age), women recorded in primary
care as having SMI and also known to secondary mental
health services were substantially less likely (with 22–28 %
lower odds) to have been screened for breast or cervical
cancer than other women in the same population. Unlike
previous studies, we were able to explore how SMI char-
acteristics beyond diagnosis were differentially associated
with screening, and to explore any potential impact on
primary care consultation frequency on screening uptake.
For cervical cancer (but not breast cancer) screening up-
take, the frequency of primary care contact is a potential
mediating factor in the relationship between SMI and
screening receipt and so the best estimates of screening
frequency and inequality are those in the models adjusted
for sociodemographic factors. However, when the higher
Table 1 Variable names, definitions and data sources
Variable Definition Data source
SMI status Recorded on the QOF Mental Health register with a diagnosis of schizophrenia, bipolar affective disorder
and other psychoses
LDN
Gender Male/female LDN
Age Date of extraction - date of birth (years) LDN
Deprivation Index of Multiple deprivation 2010 score (quintiles) LDN
ONS
Primary care
consultation
Mean annual number of GP face-to-face, telephone and home visits and nurse consultations
between October 2010–2013
LDN
Breast cancer
screening
Read code indicating breast cancer screen (mammography) & date of last screen LDN
Cervical cancer
screening
Read code indicating cervical cancer screen (smear) & date of last screen LDN
SMI diagnosis ICD-10 diagnostic code (primary and secondary diagnosis) CRIS
Depot injectable Ever recorded as prescribed depot injectable antipsychotic CRIS
SMI severity Any record of a mental health inpatient stay, treatment under the Mental Health Act, difficulty managing their physical
health as recorded in a clinical risk assessment; or contact with Assertive Outreach, Crisis team or A&E liaison team
CRIS
SMI risk Ever recorded with a history of violence, non-compliance, or a forensic history (on the risk assessment violence
and aggression subscale)
CRIS
Notes. SMI Serious Mental Illness, QOF Quality and Outcomes Framework, LDN Lambeth DataNet, CRIS Clinical Record Interactive Search; ONS Office for National
Statistics, ICD-10 International Statistical Classification of Diseases (2010)
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rates of primary care consultation for women with SMI
were taken into account, the difference in cervical
screening receipt between women with and without
SMI appeared even greater.
The negative effect sizes found in models adjusted for
sociodemographic factors were similar for both breast
and cervical screening. However, adjusting for frequency
of primary care contact had a much greater impact on
estimates of cervical than breast screening. This indicates
that frequency of primary care contact has a stronger
effect on cervical screening rates than mammographic
screening rates, as consultation frequency was elevated in
the SMI group eligible for both types of screening. This is
consistent with differences in the organisation of both
national screening programmes, cervical screening being
organised within primary care whereas breast screening
being organised via a national invitation system. Further,
unlike breast screening, cervical screening is incentivised
as part of the QOF guidelines for those recorded with
SMI. It is unclear whether this has impacted the likeli-
hood of screening uptake, though the adjusted effect size
is similar to that reported for women with schizophrenia
in a Canadian context without such incentivisation [20].
Nonetheless, breast screening rates were positively associ-
ated with frequency of primary care contact suggesting
that contact in primary care may promote mammography
uptake – perhaps via verbal reminder or encouragement
from practitioners. Kodl [21] noted that it is important to
take frequency of outpatient care contact into account
when assessing screening uptake in people with SMI, as
Table 2 Characteristics of patients eligible for mammography screening for breast and/or cervical screening, by serious mental
illness (SMI) status
Mammography eligible population Cervical smear eligible population
Non-SMI (n = 25,385) SMI (n = 625) p Non-SMI (n = 106,554) SMI (n = 1393) p
n (%) n (%)
Age group (years)a
Mammography Cervical smear 0.709 <0.001
- 25–34 - - 47449 (44.5) 261 (18.7)
- 35–44 - - 27579 (25.9) 382 (27.4)
50–54 45–54 9035 (35.6) 218 (34.9) 19910 (18.7) 454 (32.6)
55–64 55–64 11616 (45.8) 296 (47.4) 11616 (10.9) 296 (21.3)
65–70 - 4734 (18.7) 111 (17.8) - -
Ethnicity <0.001 <0.001
British/mixed British 7742 (35.8) 189 (33.4) 30953 (33.7) 362 (28.8)
Irish 528 (2.4) 24 (4.2) 1972 (2.2) 31 (2.5)
Indian/Bangladeshi/Pakistani 1423 (6.6) 44 (7.8) 5870 (6.4) 75 (6.0)
Caribbean/mixed Caribbean 3309 (15.3) 142 (25.1) 8880 (9.7) 300 (23.9)
African/mixed African 2957 (13.7) 71 (12.5) 11382 (12.4) 227 (18.1)
Chinese/other 991 (4.6) 8 (1.4) 4608 (5.0) 30 (2.4)
Other white 3741 (17.3) 59 (10.4) 23848 (25.9) 135 (10.7)
Other black 620 (2.9) 21 (3.7) 2586 (2.8) 73 (5.8)
Other mixed 307 (1.4) 8 (1.4) 1826 (2.0) 24 (1.9)
Deprivation quintile <0.001 <0.001
Most deprived 4706 (19.1) 165 (26.5) 18464 (18.0) 365 (26.4)
2 5188 (21.1) 123 (19.7) 21223 (20.7) 303 (21.9)
3 4891 (19.8) 120 (19.3) 21544 (21.0) 272 (19.7)
4 5024 (20.4) 118 (18.9) 22554 (22.0) 247 (17.9)
Least deprived 4838 (19.6) 97 (15.6) 18904 (18.4) 197 (14.2)
Consultations <0.001 <0.001
Median/below median 7222 (30.8) 64 (10.5) 42642 (44.1) 184 (13.7)
Above median 16238 (69.2) 545 (89.5) 53982 (55.9) 1158 (86.3)
aEligible age range for breast screening (mammography) 50–70 years; eligible age range for cervical cancer screening (cervical smear) 25–64 years
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not doing so may obscure differences in screening uptake,
although we report reduced screening even without
accounting for contact frequency.
Although not presented here, we re-ran analyses to
assess the possibility that the difference in screening
uptake may be less apparent if the comparison included
those ever screened in the numerator. However, the
odds associated with SMI status of ever receiving a
screen for either cancer remained very similar to ana-
lyses including just those with a recent screen, and the
pattern by SMI characteristics was also very similar
(data available from authors upon request).
In their review of breast and cervical screening among
women with a range of mental disorders, Aggarwal et al.
[7] identified a need to examine what impact illness sever-
ity and treatment have on the relationship between mental
illness and screening uptake. Our data linkage allowed us
to examine these factors by assessing predictors of screen-
ing rates within the SMI group, including diagnosis,
receipt of depot medication, and markers of severity. We
found that women with schizophrenia had the lowest
screening rates, in keeping with other studies that have
found that women with more severe mental illness are less
likely to be screened [22, 23]. Characterising people with
SMI on dimensions other than diagnosis provides a richer
understanding of which patients may be most at risk of
reduced healthcare including poorer uptake of screening.
Receipt of depot medication can be a more specific in-
dicator of severity of mental illness and engagement with
health services. This group had the lowest receipt of
screening, which may relate to reluctance to engage with
health services leading independently to low screening
uptake and the need for depot medication, but may
equally relate to difficult engagement with mental health
services making people less likely to seek out other care
such as cancer screening. Further, those prescribed
depot injectable medication may comprise a more un-
well group which may hinder uptake of screening for
Fig. 1 An illustration of Lambeth DataNet (LDN) and the Clinical Record Interactive Search (CRIS) database linkage sample. Also shown is the
population eligible for cervical and breast cancer screening, number and proportion of eligible population screened overall and screened within
Quality and Outcomes Framework (QOF) guideline periods
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Table 3 Associations between serious mental illness (SMI) status and recent receipt of breast and/or cervical screening overall and by SMI characteristic sub-group
Mammography eligible population (N = 26,010) Cervical smear eligible population (N = 107,947)
Recorded
mammography in
last 3 years n (%)
Unadjusted OR
(95 % CI)
Adjusted for
socio-demographics
ORa (95 % CI)
Additionally adjusted
for consultation rate
ORb (95 % CI)
Recorded cervical
smear in last
3/5 years n (%)
Unadjusted
OR (95 % CI)
Adjusted for
socio-demographics
ORa (95 % CI)
Additionally adjusted
for consultation rate
ORb (95 % CI)
Non-SMI 14205 (65.7) 1.00 1.00 1.00 67823 (77.8) 1.00 1.00 1.00
SMI overall 305 (58.1) 0.72 (0.61 – 0.86)*** 0.69 (0.57 – 0.84)*** 0.60 (0.49 – 0.73)*** 848 (80.2) 1.16 (0.99 – 1.35) 0.72 (0.60 – 0.85)*** 0.35 (0.29 – 0.42)***
SMI by diagnosis
Schizophrenia 136 (55.1) 0.64 (0.50 – 0.82)*** 0.59 (0.45 – 0.78)*** 0.52 (0.40 – 0.69)*** 270 (76.9) 0.95 (0.74 – 1.22) 0.48 (0.36 – 0.63)*** 0.24 (0.18 – 0.32)***
Bipolar affective disorder 67 (62.0) 0.85 (0.58 – 1.26) 0.89 (0.59 – 1.35) 0.72 (0.47 – 1.10) 231 (87.2) 1.94 (1.35 – 2.78)*** 1.23 (0.84 – 1.80) 0.50 (0.33 – 0.74)**
Other non-organic
psychoses
34 (50.8) 0.54 (0.33 – 0.87)* 0.53 (0.31 – 0.90)* 0.47 (0.27 – 0.80)** 153 (74.3) 0.82 (0.60 – 1.13) 0.57 (0.40 –0.80)** 0.33 (0.22 –0.47)***
Depot injectable
No 191 (64.3) 0.94 (0.74 – 1.20) 0.97 (0.75 – 1.26) 0.83 (0.64 – 1.09) 524 (82.3) 0.32 (1.08 – 1.62)** 0.82 (0.65 – 1.02) 0.36 (0.29 – 0.46)***
Yes 80 (49.1) 0.50 (0.37 – 0.68)*** 0.46 (0.33 – 0.64)*** 0.39 (0.27 –0.54)*** 199 (76.3) 0.92 (0.69 – 1.22) 0.48 (0.35 –0.66)*** 0.26 (0.18 – 0.36)***
Any indicator of severity1
No 168 (65.6) 1.00 (0.77 – 1.29) 0.91 (0.69 – 1.21) 0.79 (0.59 –1.06) 411 (82.2) 1.32 (1.05 – 1.66)* 0.82 (0.63 – 1.06) 0.40 (0.31 – 0.53)***
Yes 137 (50.9) 0.54 (0.43 – 0.69)*** 0.54 (0.42 –0.70)*** 0.46 (0.36 – 0.61)*** 437 (78.5) 1.04 (0.85 – 1.27) 0.65 (0.52 – 0.81)*** 0.31 (0.25 –0.40)***
Any indicator of risk2
No 205 (61.8) 0.84 (0.67 – 1.05) 0.81 (0.63–1.03) 0.70 (0.55 – 0.90)** 535 (82.1) 1.31 (1.07 – 1.60)** 0.79 (0.63 – 1.00)* 0.38 (0.30 –0.49)***
Yes 100 (51.8) 0.56 (0.42 – 0.74)*** 0.53 (0.39 –0.73)*** 0.46 (0.34 –0.63)*** 313 (77.3) 0.97 (0.77 – 1.23) 0.62 (0.48 – 0.80)*** 0.31 (0.24 – 0.41)***
Eligible population includes non-linked non-SMI and linked SMI group
*p < 0.05, **p < 0.01, ***p < 0.001
1Includes any of: ever had an inpatient stay, any record of being treated under the Mental Health Act, any record of difficulty managing their physical health, or any record of an Assertive Outreach/Crisis/A&E episode
2Includes any of: recorded history of violence, recorded history of non-compliance, and any record of a forensic history
aAdjusted for age (continuous), ethnicity, and borough-level deprivation
bAdditionally adjusted for mean annual number of primary consultations
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other unmeasured reasons. Other markers of risk and
severity were also associated with being less likely to
attend screening. Markers of risk and severity were more
strongly predictive of uptake of mammographic screening
than cervical screening. After adjustment for sociodemo-
graphic factors, women without indicators of severity or
risk and not on depot medication were not significantly
less likely than women without SMI to be screened for
breast or cervical cancer. When frequency of primary
care visits was taken into account, women without
these indicators remained not significantly less likely to
receive mammographic screening (with the exception
of those with no indicators of risk), but were less likely
to receive cervical cancer screening. This difference
may be related to mammographic screening being
offered at an unfamiliar location with unfamiliar staff,
factors which may make attendance more difficult for
those with more severe illness.
The finding of a 22–28 % reduction in screening up-
take in women with SMI after accounting for demo-
graphic factors is in keeping with the international
literature [5–7]. For example, a pooled meta-analysis
of studies of mammography uptake in the context of
mental illness found a 29 % reduction in the odds of
mammography in women with mental illness, and a
46 % reduction in women with SMI [5]. However, as
noted in the introduction, the majority of studies on
which this meta-analysis and other reviews are based
were conducted in the United States, where there are
no population - based organised screening pro-
grammes. In a previous UK study, [22] breast screen-
ing registrations were linked to mental health service
use and no difference in mammography receipt for
women known to mental health services was found
overall, but women with a psychosis diagnosis (OR
0.33) or a history of compulsory treatment (OR 0.40)
had reduced screening receipt. This study focused on
mammography and dates from nearly a decade prior
to ours, suggesting that the situation has not changed
markedly over this time. Other UK evidence suggests
that late diagnosis of cancers may not be a significant
factor in poor cancer survival people with SMI, but
this evidence comes from a study which examined all
cancers combined, and all ages, and so it is not pos-
sible to draw conclusions about stage at diagnosis of
breast or cervical cancers in screening age populations
from these results [24].
Strengths and limitations
This study is strengthened by the availability of linked
primary and secondary care data, which provides infor-
mation on mental health symptom severity, mental
health service receipt, and diagnosis to enable investi-
gation of differences within the group of people with
SMI. Further, linkage with population-based primary
care records allowed the identification of a direct com-
parison population. Information held by general prac-
tice on cervical screening is likely to be complete. Since
mammography is not performed in primary care, infor-
mation may be less complete, particularly for those
who consult less often, although we were able to adjust
for consultation frequency.
This study did not include all those who were identi-
fied as having SMI in primary care data, but was re-
stricted to those who were also known to secondary
mental health services. This group may fare better (be-
cause of higher rates of health service contact providing
more opportunities for reminders about screening) or
worse (because of having more severe illness or more
fragmented care) than those not in current contact with
secondary services, and so these findings may not apply
to the entire group registered with SMI in general prac-
tice. However, the decision to compare just those with
SMI known to secondary care was made in order to ex-
tend currently available knowledge by enabling us to
examine the role of illness/secondary mental health care
factors not available for those known only to primary
care. Whether screening rates are different for SMI pa-
tients known only to primary care may be explored in a
later study. Lastly, while our findings are representative
of a limited geographic area characterised by high levels
of deprivation – potentially limiting generalisability –
our effect sizes are consistent with those reported in
studies internationally, and indicate that screening up-
take is reduced for SMI patients even in a setting where
screening, primary care and secondary care are provided
free at the point of access.
Conclusions
This study provides up to date information about can-
cer screening in adults using mental health services in
the UK, showing that breast and cervical cancer
screening receipt is lower in women with SMI than
other women even in the context of free primary care,
organised screening and incentives to provide screen-
ing, and despite more frequent contact with primary
care. It also demonstrates that individual and treat-
ment related factors beyond diagnosis are associated
with reduced likelihood of screening. Efforts to im-
prove screening coverage for women with SMI will be
important for improving cancer survival for this group.
If we are to tackle health disparities linked to SMI
status then increasing uptake of cancer screening for
women with SMI must be a key element. Our findings
indicate the potential benefits of incorporating policies
which target efforts at encouraging greater screening
uptake among women with other markers of severity
or risk, beyond SMI status alone.
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